KR900002780A - 노화와 건망증에 관련된 인식 및 행동장애에 대한 자료 - Google Patents

노화와 건망증에 관련된 인식 및 행동장애에 대한 자료 Download PDF

Info

Publication number
KR900002780A
KR900002780A KR1019890011697A KR890011697A KR900002780A KR 900002780 A KR900002780 A KR 900002780A KR 1019890011697 A KR1019890011697 A KR 1019890011697A KR 890011697 A KR890011697 A KR 890011697A KR 900002780 A KR900002780 A KR 900002780A
Authority
KR
South Korea
Prior art keywords
morpholino
propyl
triazine
amino
alkyl
Prior art date
Application number
KR1019890011697A
Other languages
English (en)
Other versions
KR0137660B1 (ko
Inventor
에른스트 뷜퍼
장 고베르
에릭 코세망
Original Assignee
알.두쎌도르프, 아이.시.아이. 에이
유시비 에스.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알.두쎌도르프, 아이.시.아이. 에이, 유시비 에스.에이 filed Critical 알.두쎌도르프, 아이.시.아이. 에이
Publication of KR900002780A publication Critical patent/KR900002780A/ko
Application granted granted Critical
Publication of KR0137660B1 publication Critical patent/KR0137660B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

노화와 건망증에 관련된 인식 및 행동장애에 대한 치료
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 노화와 건망증에 관련된 인식 및 행동장해를 치료하기 위해, 다음 일반식(Ⅰ)의 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진 또는 이들의 제약학적으로 수용가능한 비독성 산부가염을 유효량 투여하는 것으로 이루어지는, 노화와 건망증에 관련된 인식 및 행동장해를 치료하기 위한 방법.
    상기식에서 R1은 수소원자, 알킬, 아르알킬 또는 아세틸기를 나타내고, R2는 수소원자, 히드록실그룹, 알킬히드록시알킬, 알콕시알킬, 디알킬아미노, 아릴-히드록시알킬, (히드록시-시클로알킬)알킬, 알칼오일옥시알킬, 벤조일옥시알킬, 페닐아세틸옥시알킬 또는 아미노카르보닐옥시알킬기, R3가 알킬, 아릴, 할로아릴, 알킬아릴, 알콕시아릴, 아르알킬 또는 아릴옥시기를 나타내는 COR3그룹을 나타내거나 또는, R4와 R5가 수소원자 또는 알킬기를 나타내는 CONR4R5그룹을 나타내고, 또는 R1과 R2는 이들이 부착되는 질소원자와 함께 히드록시알킬기에 의해 치환된 알킬렌이미노기를 나타내며, 알킬, 알콕시 및 알칼오일옥시기는 C1-C4를 가지며 시클로알킬 및 알킬렌이미노기는 C4-C6를 가지고, 단 R1이 아세틸기를 나타낸때, R2는 아세톡시알킬기를 나타낸다.
  2. 제 1 항에 있어서, 치료적 유효량이 하루에 0.1 내지 2g임을 특징으로 하는 방법.
  3. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진 히드로클로라이드임을 특징으로 하는 방법.
  4. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-(메틸아미노)-4-모폴리노-6-프로필-1,3,5-트리아진 히드로클로라이드임을 특징으로 하는 방법.
  5. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-[(4-모폴리노-6-프로필-1,3,5-트리아진-2-일)아미노]-에탄올임을 특징으로 하는 방법.
  6. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-(히드록시아미노)-4-모폴리노-6-프로필-1,3,5-트리아진임을 특징으로 하는 방법.
  7. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-[(2-메톡시에틸)아미노]-4-모폴리노-6-프로필-1,3,5-트리아진임을 특징으로 하는 방법.
  8. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 (S)-3-[(4-모폴리노-6-프로필-1,3,5-트리아진-2-일)아미노]-2-프로판올임을 특징으로 하는 방법.
  9. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 (R)-3-[(4-모폴리노-6-프로필-1,3,5-트리아진-2-일)아미노]-2-프로판올임을 특징으로 하는 방법.
  10. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-(2,2-디메틸히드라지노)-4-모폴리노-6-프로필-1,3,5-트리아진임을 특징으로 하는 방법.
  11. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 N-(4-모폴리노-6-프로필-1,3,5-트리아진-2-일)-벤즈아미드 히드로클로라이드임을 특징으로 하는 방법.
  12. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 N-메틸-N-(4-모폴리노-6-프로필-1,3,5-트리아진-2-일)벤즈아미드 히드로클로라이드임을 특징으로 하는 방법.
  13. 제 1 항에 있어서, 2-아미노-4-모폴리노-6-프로필-1,3,5-트리아진이 2-[[(2-(아세톡시)에틸]아미노]-4-모폴리노-6-프로필-1,3,5-트리아진임을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890011697A 1988-08-16 1989-08-16 노화와 치매증에 관련된 인식 및 행동장애 치료제 KR0137660B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8819494.9 1988-08-16
GB888819494A GB8819494D0 (en) 1988-08-16 1988-08-16 Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments

Publications (2)

Publication Number Publication Date
KR900002780A true KR900002780A (ko) 1990-03-23
KR0137660B1 KR0137660B1 (ko) 1998-05-15

Family

ID=10642236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890011697A KR0137660B1 (ko) 1988-08-16 1989-08-16 노화와 치매증에 관련된 인식 및 행동장애 치료제

Country Status (15)

Country Link
US (1) US4956363A (ko)
EP (1) EP0356412B1 (ko)
JP (1) JPH02108676A (ko)
KR (1) KR0137660B1 (ko)
AT (1) ATE75942T1 (ko)
AU (1) AU616140B2 (ko)
CA (1) CA1329772C (ko)
DE (1) DE68901511D1 (ko)
DK (1) DK398289A (ko)
GB (1) GB8819494D0 (ko)
IE (1) IE61828B1 (ko)
IL (1) IL91244A (ko)
MY (1) MY104150A (ko)
PH (1) PH26119A (ko)
ZA (1) ZA896223B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024617D0 (en) * 1989-12-05 1991-01-02 Ici Plc Heterocyclic compounds
GB9008818D0 (en) * 1990-04-19 1990-06-13 Ici Plc Amine derivatives
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
GB9116039D0 (en) * 1991-07-25 1991-09-11 Ucb Sa Substituted cyclopropylamino-1,3,5-triazines
DE19531084A1 (de) 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AU781849C (en) * 1999-06-17 2006-03-02 Synta Pharmaceuticals Corp. Inhibitors of IL-12 production
WO2005030735A1 (en) * 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Triazines derivatives as cell adhesion inhibitors
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
EP3006023B1 (en) 2009-01-20 2019-06-26 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic acid and derivatives thereof to enhance the activity of a neuropharmaceutical
WO2016204988A1 (en) * 2015-06-18 2016-12-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Autophagy modulators for treating neurodegenerative diseases
KR102338171B1 (ko) 2016-06-13 2021-12-09 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산리튬의 공-결정 및 그의 용도
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549755A (en) * 1968-03-27 1970-12-22 Shell Oil Co Use of 2-trichloromethyl-4-morpholinoor piperazino-6-substituted-s-triazines for inducing depressant effects in animals
FR2262512A1 (en) * 1974-03-01 1975-09-26 Synthelabo 2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity

Also Published As

Publication number Publication date
EP0356412A1 (fr) 1990-02-28
IE61828B1 (en) 1994-11-30
AU616140B2 (en) 1991-10-17
DK398289A (da) 1990-02-17
ATE75942T1 (de) 1992-05-15
GB8819494D0 (en) 1988-09-21
MY104150A (en) 1994-02-28
DE68901511D1 (de) 1992-06-17
IL91244A (en) 1994-07-31
DK398289D0 (da) 1989-08-14
JPH02108676A (ja) 1990-04-20
CA1329772C (en) 1994-05-24
KR0137660B1 (ko) 1998-05-15
IE892620L (en) 1990-02-16
AU3991889A (en) 1990-02-22
EP0356412B1 (fr) 1992-05-13
ZA896223B (en) 1990-05-30
US4956363A (en) 1990-09-11
PH26119A (en) 1992-02-24
IL91244A0 (en) 1990-03-19

Similar Documents

Publication Publication Date Title
KR900002780A (ko) 노화와 건망증에 관련된 인식 및 행동장애에 대한 자료
DE69426331D1 (de) Arzneimittel gegen nervöse erkrankungen
NO940737L (ko)
DK0483772T3 (da) Aminocumaranderivater, samt fremstilling og anvendelse deraf
ES2106573T3 (es) Composicion oftalmica que contiene un derivado de 1,5-benzoxatiepina para tratar glaucoma.
HUP0303514A2 (hu) AlfavBéta6 integrin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0561941T3 (da) N-Substituerede lactamer anvendelige som cholecystokinin-antagonister
ATE202784T1 (de) Streptogramine in gereinigter form, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
ES2091359T3 (es) Nuevo compuesto peptidico y un procedimiento para su preparacion.
ES2156933T3 (es) Derivados triciclicos de benzazepina y benzotiazepina.
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
ES2001697A6 (es) Procedimiento para preparar 2-aminopurinas sustituidas en posiciones 6 y 9
PT97571A (pt) Processo para a prparacao de hidrazonas
DE3472255D1 (en) Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.
KR900003165A (ko) 2-아미노-4-모르폴리노-6-프로필-1,3,5-트리아진
ATE196287T1 (de) Verfahren zur herstellung von 2-hydroyalkyl paraphenylendiaminen, neue 2-hydroxyalkyl paraphenylendiamine, deren verwendung zum oxidativen färben, färbemittel und färbeverfahren
TH6968A (th) ไตรสับสทิทิวด์ 1,3,5-ไตรเอซีน 2,4,6-ไตรโอน
TH900A (th) สารฆ่าวัชพืชอินโดลซัลโฟนามีด

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee